Quality Assurance (QA) Manager to Nanexa AB
Nanexa is now recruiting a Quality Assurance (QA) Manager. The position is full-time and based...
Read more
Nanexa’s PharmaShell® technology is transforming the face of long-acting ’super generic’ drugs with its proprietary suite of Atomic Layer Deposition (ALD) technologies.
PharmaShell formulations will allow indications including type 2 diabetes/obesity, cancers, cardiovascular and psychiatric disorders to be treated with monthly injections.
18 June, 2026
An intensive first half-year sets the stage for an interesting continuation
READ MORE12 May, 2026
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 12, 2026, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
READ MORE18–20 May 2026
29 April 2026
19 February 2026
11 December 2025